7PL.F Stock Analysis
7P
Uncovered
ProstaLund AB is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
ProstaLund AB engages in the development and marketing of medical technology within urology. The company is headquartered in Lund, Skane. The company went IPO on 2013-10-24. The firm develops and manufactures urological devices and treatments primarily for benign prostatic hyperplasia (BPH). The firm develops CoreTherm, a patented Thermotherapy treatment method for BPH, which takes approximately 6-15 minutes and offers long-term symptom relief. CoreTherm is used in hospitals and clinics in Sweden and worldwide.